吡仑帕奈作为添加治疗用于难治性癫痫持续状态和缺氧后脑病:一项真实世界单中心回顾性队列研究
该单中心回顾性队列纳入2018年1月至2022年12月连续成人难治性癫痫持续状态患者36例(非缺氧性29例、缺氧后脑病7例),评估吡仑帕奈添加治疗的临床与脑电图结局。非缺氧性亚组45%(13/29;95%CI 27-63%)为应答者,34%(10/29;95%CI 17-52%)为部分应答,21%(6/29;95%CI 6-35%)无应答;缺氧后脑病亚组无完全应答,43%(3/7;95%CI 6-80%)部分应答,57%(4/7;95%CI 20-95%)无应答。两亚组中应答者与无应答者住院时长无显著差异;非缺氧性亚组应答者出院时改良Rankin量表评分中位数3(四分位距3-4),无应答者5(四分位距5-6)。作者认为吡仑帕奈在非缺氧性难治性癫痫持续状态中中等剂量下似有前景,缺氧后脑病中疗效似乎较低,需进一步研究确认。
要点
- 非缺氧性难治性癫痫持续状态患者中,吡仑帕奈添加治疗应答率45%(13/29;95%CI 27-63%),部分应答34%(10/29;95%CI 17-52%),无应答21%(6/29;95%CI 6-35%)。
- 缺氧后脑病亚组(n=7)无完全应答,部分应答43%(3/7;95%CI 6-80%),无应答57%(4/7;95%CI 20-95%)。
- 非缺氧性亚组应答者出院时改良Rankin量表评分中位数3(四分位距3-4),无应答者5(四分位距5-6)。
- 两亚组中应答者与无应答者住院时长均无显著差异。
- 作者认为吡仑帕奈在非缺氧性难治性癫痫持续状态中中等剂量下似有前景,缺氧后脑病中疗效似乎较低,需进一步研究确认。
适用人群与场景
- 连续成人难治性癫痫持续状态患者,包括缺氧后脑病患者,脑电图显示癫痫持续状态模式,2018年1月至2022年12月在本中心接受治疗。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究;样本量36例,其中非缺氧性难治性癫痫持续状态29例、缺氧后脑病7例。
- 非缺氧性亚组:应答45%(13/29;95%CI 27-63%),部分应答34%(10/29;95%CI 17-52%),无应答21%(6/29;95%CI 6-35%)。
- 缺氧后脑病亚组(n=7):无完全应答;部分应答43%(3/7;95%CI 6-80%),无应答57%(4/7;95%CI 20-95%)。
- 应答者与无应答者基线特征重叠。
- 两亚组中应答者与无应答者住院时长均无显著差异。
- 非缺氧性亚组应答者出院时改良Rankin量表评分中位数3(四分位距3-4),无应答者5(四分位距5-6)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:回顾性设计和小样本量,作者指出需进一步研究确认这些观察结果。
对床旁实践的改变
- 作者认为,吡仑帕奈作为添加治疗在非缺氧性难治性癫痫持续状态中中等剂量下似乎产生有前景的结果,包括出院时功能结局有更好趋势,且无显著不良反应。
- 作者认为,在缺氧后脑病患者中,该药似乎表现欠佳、疗效较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Data on the efficacy of perampanel in refractory status epilepticus (RSE) and postanoxic encephalopathy (PAE) are limited; its use in such conditions is currently off-label.
METHODS: We conducted a retrospective cohort study of consecutive adult patients with RSE, including PAE, exhibiting electroencephalographic patterns indicative of status epilepticus who were treated at our center (January 2018 to December 2022) with assessment of clinical and electroencephalographic outcomes.
RESULTS: Thirty-six patients were included in the study, of whom 29 had nonanoxic RSE and 7 had PAE. Within the nonanoxic RSE subgroup, 45% (13 of 29; 95% confidence interval [CI] 27-63%) of study participants were responders, 34% (10 of 29; 95% CI 17-52%) were partial responders, and 21% (6 of 29; 95% CI 6-35%) were nonresponders. In the PAE subgroup (n = 7), no patients fully responded to perampanel; 43% (3 of 7; 95% CI 6-80%) were partial responders, and 57% (4 of 7; 95% CI 20-95%) were nonresponders. Responder and nonresponder study participants exhibited overlapping baseline characteristics. No significant differences in duration of hospitalization were observed between responders and nonresponders in both subgroups. Responders in the RSE subgroup had a median discharge modified Rankin Scale score of 3 (interquartile range 3-4), and nonresponders had a median discharge modified Rankin Scale score of 5 (interquartile range 5-6).
CONCLUSIONS: Despite limitations from the retrospective design and the small population size, this study suggests that perampanel use in nonanoxic RSE appears to yield promising results at moderate doses, including a tendency toward a better functional outcome at discharge, without significant adverse effects. However, in patients with PAE, the drug seems to show suboptimal performance. Perampanel appears to have promising efficacy as an add-on therapy in nonanoxic RSE. However, in patients with PAE, its efficacy seems to be lower. Further studies are warranted to confirm these observations.
参考来源
- Cutillo G, Bonacchi R, Vabanesi M, et al. Perampanel as an Add-On Therapy in Patients with Refractory Status Epilepticus and Postanoxic Encephalopathy: A Real-Life Single-Center Retrospective Cohort Study. Neurocrit Care. 2024. PMID: 38872031. doi:10.1007/s12028-024-02019-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。